Malignant Tumor, Neoplasms, Solid Tumors
Conditions
Keywords
ES101, solid tumor, phase 1, PD-L1, 4-1BB, INBRX-105, PD-L1×4-1BB, 41BB, PDL1
Brief summary
The purpose of this study is to evaluate the safety, tolerance and Dose-Limiting Toxicity (DLT) of recombinant humanized PD-L1/4-1BB bispecific antibody (ES101) in patients with advanced solid tumors.
Detailed description
ES101 (INBRX-105; PDL1x4-1BB antibody) is a recombinant humanized bispecific IgG1 antibody targeting human PD-L1 and 4-1BB. This is an open-label, multicenter, dose-escalation and cohort expansion phase 1 clinical study to evaluate the safety and pharmacokinetic characteristics and preliminary anti-tumor activity of ES101 in patients with advanced malignant solid tumors whose disease has progressed despite standard therapy, or who has no further standard therapy, or who is unsuitable for available standard treatment options.
Interventions
DRUGES101
ES101 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle.
Sponsors
Elpiscience Biopharma, Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Males or females aged ≥ 18 years. 2. Subject has pathological or cytological diagnosed advanced malignant solid tumor, whose disease has progressed despite standard therapy, or who has no further standard therapy, or who is unsuitable for available standard treatment options 3. Part A: There is no mandatory requirement for PD-L1 expression status of subject's tumor tissue. Part B:Tumor tissue of subject should be PD-L1 positivity by immunohistochemistry (IHC). 4. Subjects in part A shall have at least one evaluable lesion, and subjects enrolled in part B shall have at least one measurable lesion (RECIST v1.1). Tumor lesions located in previously irradiated (or other local treated) areas will be considered measurable, provided that there has been clear imaging-based progression of the lesions since the time of radiation. 5. Adequate hematologic, coagulation, hepatic and renal function as defined per protocol. 6. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1. 7. Estimated life expectancy, in the judgment of the investigator, of at least 12 weeks. 8. Male and female subjects of childbearing potential and their spouses must be willing to use feasible contraceptive methods considered effective by the investigator, from the time of signing informed consent and for the duration of study participation through 3 months, following the last dose of study drug. Postmenopausal women are considered to have no fertility potential only if menostasis lasts for at least 12 months. 9. Ability to understand and the willingness to sign a written informed consent form
Exclusion criteria
1. Prior exposure to 4-1BB agonists. 2. Receipt of any anticancer investigational product or any approved drug(s) or biological products (except hormone-replacement therapy, testosterone or oral contraceptives) within 4 weeks prior to the first dose of study drug. Previous exposure to oral fluorouracils or small molecular targeted drugs require a minimum washout period of 2 weeks or 5 half-lives prior to the first dose of study drug (whichever is longer). Previous exposure to mitomycin C or nitrosourea requires a minimum washout period of 6 weeks prior to the first dose of study drug. 3. Known allergies to CHO-produced antibodies, which in the opinion of the Investigator suggests an increased potential for an adverse hypersensitivity to ES101. 4. Primary or metastatic brain or meningeal tumors. 5. Patients with other malignancies previously or currently shall be excluded in Part B. 6. Grade ≥ 3 immune-related adverse events (irAEs) or irAE that lead to discontinuation of prior immunotherapy. Some exceptions as defined per protocol apply. 7. Active autoimmune disease or documented history of autoimmune disease that required systemic steroids or other immunosuppressive medications. Certain exceptions as defined in protocol apply. 8. Treatment with systemic immunosuppressive medications within 4 weeks prior to the first dose of study drug. Certain exceptions as defined in protocol apply. 9. Active interstitial lung disease (ILD) or pneumonitis or a history of ILD or pneumonitis requiring treatment with steroids or immunosuppressive medications.. 10. Subjects who received G-CSF, GM-CSF, Thrombopoietic drugs or EPO within 14 days prior to the first dose of the study drug. 11. Any evidence of hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection. 12. History of hepatitis (non-alcohol steatohepatitis, alcohol or drug-related, autoimmune) or cirrhosis. 13. Clinically significant cardiac condition. 14. History of pulmonary embolism within 12 weeks prior to the first dose of study drug. 15. Major surgery within 4 weeks prior to enrollment on this trial. 16. Systemic anti-infectious drug treatments within 4 weeks prior to the first dose of study drug. 17. Prior organ allograft transplantations or allogeneic peripheral blood stem cell (PBSC) or bone marrow (BM) transplantation. 18. Live viral vaccine therapies within 4 weeks prior to the first dose of study drug. 19. Subject has not recovered from all AEs of previous anticancer therapies to baseline or ≤ Grade 1 per CTCAE v5.0 before teh first dose of study drug. Certain exceptions as defined in protocol apply. 20. Pregnant or nursing females. 21. Any known, documented, or suspected history of substance abuse that would preclude subject from participation, unless clinically justified (i.e., will not interfere with study participation and/or will not compromise trial objectives) per judgment of the Investigator and with approval of the Medical Monitor or Study Director. 22. The subject is inappropriate to participate in this study for other reasons in the judgment of the Investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of of ES101 | Up to 2-3 years | The MTD and/or RP2D of ES101 will be determined. |
| Frequency of adverse events of ES101 | Up to 2-3 years | Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0. |
| Severity of adverse events of ES101 | Up to 2-3 years | Severity of adverse events will be assessed and assigned by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to Cmax (Tmax) of ES101 | Up to 2-3 years | Time to Cmax (Tmax) of ES101 will be determined. |
| Area under the serum concentration time curve (AUC) of ES101 | Up to 2-3 years | Area under the serum concentration time curve (AUC) of ES101 will be determined. |
| Anti-tumor activity of ES101 | Up to 2-3 years | Tumor response will be determined by the revised Response Evaluation Criteria in Solid Tumors version 1.1 (RECISTv1.1). |
| Immunogenicity of ES101 | Up to 2-3 years | Frequency of anti-drug antibodies (ADA) against ES101 will be determined. |
| Maximum observed serum concentration (Cmax) of ES101 | Up to 2-3 years | Maximum observed serum concentration (Cmax) of ES101 will be determined. |
| Trough observed serum concentration (Ctrough) of ES101 | Up to 2-3 years | Trough observed serum concentration (Cmax) of ES101 will be determined. |
Countries
China
Outcome results
None listed